Multicenter phase II trial of mFOLFOX6 with cetuximab as active chemotherapy regimen for liver metastases inappropriate for curative resection in EGFR positive and KRAS wild type colorectal cancer - FOCAL trial

Tohoku - Six Universities Research Group by Experts (T-SURGE)0 个研究点目标入组 50 人开始时间: 2010年12月8日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Uncontrolled extrahepatic lesion (2) Symptomatic brain metastasis (3) Cardiac disease (over Grade 2 by CTCAE v4.0), or myocardial infarction within 1 year (4) Past or current history (within 5 years) of malignant disease, except for the early cancer healed clearly (5) Interstitial lung disease, or pulmonary fibrosis (6) Serious infectious disease (7) Serious complication (kidney failure, liver failure , hypertension, etc) (8) Peripheral neuropathy (over Grade 1 by CTCAE v4.0) (9) No willing of birth-control. Or pregnant or lactating women (10) Serious drug hypersensitivity or history of drug allergy of Fluorouracil, Levofolinate calcium and/or Oxaliplatin (11) Participation in other clinical trial within 4 weeks (12) History of serious drug hypersensitivity (13) Previously received on anti-EGFR antibody (14) Case whom investigator deny the enrollment

发起方

Tohoku - Six Universities Research Group by Experts (T-SURGE)